ArticleFrontiers in immunology2022
High PIRCHE Scores May Allow Risk Stratification of Borderline Rejection in Kidney Transplant Recipients.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Association of PIRCHE scores and allograft injury in kidney transplant recipients.Frontiers in immunology · 2026Observational
- Simulation of prospective PIRCHE-II molecular matching in Canada: a feasibility study.Frontiers in immunology · 2026Article
- Evaluation of dnDSA risk stratification using the updated PIRCHE-T2 model in two kidney transplant cohorts.Frontiers in immunology · 2026Article
- ScRNA profiling of peripheral blood in kidney transplant recipients across rejection responses and treatments.Scientific data · 2025Article
- Article
- Advancing risk stratification in kidney transplantation: integrating HLA-derived T-cell epitope and B-cell epitope matching algorithms for enhanced predictive accuracy of HLA compatibility.Frontiers in immunology · 2025Article
- Kidney Transplant Outcomes With Non-Depleting Antibody Induction Therapy in Human Leucocyte Antigen Sensitised Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- PIRCHE-II Risk and Acceptable Mismatch Profile Analysis in Solid Organ Transplantation.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Assessing the Predictive Power of PIRCHE-II Scores for the Development ofTransplant international : official journal of the European Society for Organ Transplantation · 2024Article
- A transitional B-cell cytokine biomarker for risk stratifying renal transplant patients with borderline rejection.Kidney international · 2023Article
- The number of donor HLA-derived T cell epitopes available for indirect antigen presentation determines the risk for vascular rejection after kidney transplantation.Frontiers in immunology · 2022Article
- PIRCHE-II scores prove useful as a predictive biomarker among kidney transplant recipients with rejection: An analysis of indication and follow-up biopsies.Frontiers in immunology · 2022Article
- Progress in kidney transplantation: The role for systems immunology.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of borderline rejection (BLR) ranges from mild inflammation to clinically significant TCMR and is associated with an increased risk of allograft dysfunction. Currently, there is no consensus regarding its treatment due in part to a lack of biomarkers to identify cases with increased risk for immune-mediated injury.
methodsWe identified 60 of 924 kidney transplant recipients (KTRs) with isolated and untreated BLR. We analyzed the impact of predicted indirectly recognizable HLA epitopes (PIRCHE) score on future rejection,
resultsTotal PIRCHE scores were significantly higher in KTRs with BLR compared to the entire study population (p=0.016). Among KTRs with BLR total PIRCHE scores were significantly higher in KTRs who developed TCMR/ABMR in follow-up biopsies (p=0.029). Notably, the most significant difference was found in PIRCHE scores for the HLA-A locus (p=0.010). PIRCHE scores were not associated with the development of
conclusionsHigh PIRCHE scores put KTRs with BLR at an increased risk for future TCMR/ABMR and contribute to improved immunological risk stratification. The benefit of anti-rejection treatment, however, needs to be evaluated in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.